Valuation: argenx SE

Market Cap 55.41B 47.97B 44.83B 40.98B 77.22B 5,284B 78.42B 526B 206B 2,644B 208B 204B 8,805B P/E 2026 *
31.6x
P/E 2027 * 25.4x
Enterprise Value 49.99B 43.28B 40.45B 36.97B 69.67B 4,768B 70.76B 474B 186B 2,385B 188B 184B 7,944B EV / Sales 2026 *
8.07x
EV / Sales 2027 * 6.25x
Free-Float
99.98%
Yield 2026 *
0.05%
Yield 2027 * 0.09%
1 day+0.50%
1 week+6.20%
Current month+2.95%
1 month+0.42%
3 months+14.34%
6 months+8.18%
Current year+7.00%
1 week 734
Extreme 734
777.4
1 month 717.4
Extreme 717.4
829.2
Current year 568.4
Extreme 568.4
833.6
1 year 544.2
Extreme 544.2
833.6
3 years 271
Extreme 271
833.6
5 years 224.1
Extreme 224.1
833.6
10 years 12.5
Extreme 12.5
833.6
Manager TitleAgeSince
Chief Executive Officer 47 2026-05-05
Director of Finance/CFO 56 2021-05-31
Chief Tech/Sci/R&D Officer - 2014-12-31
Director TitleAgeSince
Chairman 54 2026-05-05
Director/Board Member 76 2015-05-12
Director/Board Member 65 2016-04-27
Date Insider Type Main position Quantity % Market Cap.
11/23/25 Sell

Director

4,680 0.0076%
11/23/25 Fiscal year

Director

4,680 0.0076%
11/23/25 Fiscal year

Chief Executive Officer

2,000 0.0032%
Change 5-day change 1-year change 3-year change Capi.($)
+0.50%+6.20%+34.94%+67.83% 55.41B
+4.21%+25.56%+77.96%+104.49% 70.85B
+2.78%+36.87%+23.00%+493.09% 29.43B
+1.78%+18.87%+57.08%+5.18% 24.12B
-0.93%+0.60%-16.89%-12.00% 23.31B
-0.35%+7.91%+44.14%-22.61% 18.37B
+1.42%+10.84%+31.14%+628.97% 16.1B
+7.26%+14.16%+221.03%+393.89% 16.99B
-2.05%-3.81%+40.40%+150.40% 13.12B
+0.78%+2.70%+437.94%+204.90% 12.48B
Average +1.07%+8.99%+95.07%+201.41% 28.02B
Weighted average by Cap. +1.67%+11.01%+72.03%+165.79%

Financials

2026 *2027 *
Net sales 6.2B 5.37B 5.01B 4.58B 8.64B 591B 8.77B 58.81B 23.08B 296B 23.27B 22.76B 985B 7.61B 6.59B 6.16B 5.63B 10.61B 726B 10.77B 72.22B 28.34B 363B 28.58B 27.95B 1,209B
Net income 1.86B 1.61B 1.51B 1.38B 2.6B 178B 2.64B 17.69B 6.94B 88.93B 7B 6.85B 296B 2.47B 2.14B 2B 1.83B 3.45B 236B 3.5B 23.48B 9.21B 118B 9.29B 9.09B 393B
Net Debt -5.42B -4.69B -4.38B -4.01B -7.55B -517B -7.67B -51.4B -20.17B -258B -20.34B -19.9B -861B -7.83B -6.77B -6.33B -5.79B -10.91B -746B -11.08B -74.26B -29.14B -373B -29.38B -28.74B -1,244B
Logo argenx SE
argenx SE is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx SE aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx SE developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker and is evaluating its broad potential in multiple serious autoimmune diseases while advancing several earlier stage experimental medicines within its therapeutic franchises.
Employees
1,863
Date Price Change Volume
26-08-10 €767.00 +0.50% 54,134
26-08-07 €763.20 +1.25% 48,751
26-08-06 €753.80 +0.69% 83,469
26-08-05 €748.60 +2.83% 101,341
26-08-04 €728.00 +0.80% 89,773
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
885.99USD
Average target price
1,037.68USD
Spread / Average Target
+17.12%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ARGX Stock